| Marc R. Hyman | |
|---|---|
| Photo placeholder | |
| Affiliations | Columbia University |
| Country | USA |
| H-index | 60 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Neuroimaging |
Marc R. Hyman is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hyman has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at Columbia University, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease--TEMP--/diseases)--FIX--.
The lab emphasizes Neuroimaging to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Hyman's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's disease." Alzheimers Dement (2025). DOI
Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI
Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI
Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's disease." Alzheimers Dement (2025). DOI: 10.1002/alz.70907 PubMed: 41249714
Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI: 10.1002/advs.202303381 PubMed: 37882348
Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI: 10.1117/1.NPh.12.3.035007 PubMed: 40809089
Collaborator network pending enrichment.
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). DOI)
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI)
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI)
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). [DOI: 10.1002/alz.70907]https://doi.org/10.1002/alz.70907) PubMed: 41249714
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). [DOI: 10.1002/advs.202303381]https://doi.org/10.1002/advs.202303381) PubMed: 37882348
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). [DOI: 10.1117/1.NPh.12.3.035007]https://doi.org/10.1117/1.NPh.12.3.035007) PubMed: 40809089
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). DOI)
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI)
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI)
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). [DOI: 10.1002/alz.70907]https://doi.org/10.1002/alz.70907) PubMed: 41249714
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). [DOI: 10.1002/advs.202303381]https://doi.org/10.1002/advs.202303381) PubMed: 37882348
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). [DOI: 10.1117/1.NPh.12.3.035007]https://doi.org/10.1117/1.NPh.12.3.035007) PubMed: 40809089
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). DOI)
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI)
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI)
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). [DOI: 10.1002/alz.70907]https://doi.org/10.1002/alz.70907) PubMed: 41249714
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). [DOI: 10.1002/advs.202303381]https://doi.org/10.1002/advs.202303381) PubMed: 37882348
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). [DOI: 10.1117/1.NPh.12.3.035007]https://doi.org/10.1117/1.NPh.12.3.035007) PubMed: 40809089
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). DOI)
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). DOI)
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). DOI)
[Hyman M et al.. "Mesoscopic vascular alterations in Alzheimer's Disease." Alzheimers Dement (2025). [DOI: 10.1002/alz.70907]https://doi.org/10.1002/alz.70907) PubMed: 41249714
[Chang S et al.. "Multi-Scale Label-Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two-Photon Microscopy." Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023). [DOI: 10.1002/advs.202303381]https://doi.org/10.1002/advs.202303381) PubMed: 37882348
[Abdelhakeem AA et al.. "Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy." Neurophotonics (2025). [DOI: 10.1117/1.NPh.12.3.035007]https://doi.org/10.1117/1.NPh.12.3.035007) PubMed: 40809089
Recent work by [Marc Hyman--TEMP--/researchers)--FIX-- advances understanding of genomics, computational biology, and systems approaches to [Alzheimer's disease--TEMP--/diseases)--FIX--.
The study of Marc R. Hyman has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.